Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.
about
Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.Survivors Remorse: antibody-mediated protection against HIV-1.A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure.Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals.Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters.Latently and uninfected healthcare workers exposed to TB make protective antibodies against Mycobacterium tuberculosis.Delineating antibody recognition against Zika virus during natural infectionA human inferred germline antibody binds to an immunodominant epitope and neutralizes Zika virus.Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design.Hope for HIV control in southern Africa: The continued quest for a vaccine.Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.HIV-1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanismsTailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies.HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies.Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding.Optimal immunization cocktails can promote induction of broadly neutralizing Abs against highly mutable pathogens.Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer.Progress toward active or passive HIV-1 vaccination.Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodiesDifferential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers.Driving HIV-1 into a Vulnerable Corner by Taking Advantage of Viral Adaptation and Evolution.Vaccine nanoparticles for protection against HIV infection.Breaching peripheral tolerance promotes the production of HIV-1-neutralizing antibodies.Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV.The impact of structural biology in medicine illustrated with four case studies.Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes.Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires.Genetic and structural analyses of affinity maturation in the humoral response to HIV-1.Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem.Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.Identification and specificity of broadly neutralizing antibodies against HIVUniversal antiretroviral regimens: thinking beyond one-pill-once-a-day.Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice.Natural Killer (NK) Cell Education Differentially Influences HIV Antibody-Dependent NK Cell Activation and Antibody-Dependent Cellular Cytotoxicity.Unlocking HIV-1 Env: implications for antibody attack.Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge.Characterization of a stable HIV-1 B/C recombinant, soluble and trimeric envelope glycoprotein (Env) highly resistant to CD4-induced conformational changes.Vaccine-induced immune responses against both Gag and Env improve control of simian immunodeficiency virus replication in rectally challenged rhesus macaques.The Effect of N-Terminal Cyclization on the Function of the HIV Entry Inhibitor 5P12-RANTES.Open and closed structures reveal allostery and pliability in the HIV-1 envelope spike.
P2860
Q30234773-4D57B5A0-504A-48B7-AE90-9DD003462920Q30238730-F09A2008-1FF0-40FE-9AAB-32471C5345CBQ33592001-88B929F4-0FE7-475B-AE95-3426575492E2Q33594304-4E4B1115-8937-477F-863A-5DCFAB18FA8DQ33638320-A4B3C8D0-A824-4230-B84B-07B03DFE0B6CQ33719289-C77DA1BE-E594-4622-8A4B-D8599C81E2A7Q33798068-D9AB9CE6-8AC3-49E2-9CBD-48C53BE965E0Q33825684-9A9A972A-C667-4B35-B65D-BE0176D94B5AQ36287539-6B5B623D-FDE9-4E04-A2A2-CE5A8D8852F6Q36292784-85B4A87E-74E6-4D4E-9727-6B7D02552983Q36303368-22EFF822-1BE6-44FB-B532-CC47ED2B7006Q37221386-6BF73524-1480-45A9-98FB-48C05E988FC9Q37246321-2A6B1B96-AE8A-47F5-AEB9-F1630C6A61F5Q37293480-EFBB6B4A-5C64-45A8-892D-3A4DE0AB6436Q37415418-D92C4376-51D7-4462-9742-05B1971C566CQ37417794-91DBC884-8C49-40F2-BA14-F0A476B05E81Q37482035-5064CC41-FE10-4DD7-B602-6DCBF5F6C60CQ37549777-DE2D3289-E00E-459A-9A89-FFEE1DDC1443Q37621530-73327774-E62A-4730-965D-23E96B56ECB0Q37695592-9A71D664-6DF1-4F29-8DC5-EC61BF71AF54Q37703084-304DF0FA-9C8B-4FAF-8E82-2EAFB822BF1BQ38405327-CD08B7A9-5437-41A7-B606-DFF87CB29644Q38683449-5F6119EB-B68F-4F6D-84F3-F3839123C24FQ38688524-A13A2D3F-8F27-40B8-AF9A-CFD0CB401CFFQ38698199-51CFE8F0-9D5C-4E00-9A57-695A041B2A4BQ38708708-39531B42-5359-4FCF-B576-31413BEF06FBQ38747466-AFF77804-EF78-441F-84D6-DA578B56970BQ38992744-65F5D07D-73B2-4964-8EF8-25850BEFD0E3Q39108730-97EBBE42-0868-4557-B3B4-4DEA7D8D04C6Q39108735-68D74B2B-1C5D-43D6-889B-66EEFE764159Q39108796-D588D80C-CC45-4DC4-902E-37A87AE06DCEQ39215169-EB8C977B-515E-4CF8-AEE6-507B3563F0A7Q39407795-4A1B408C-3431-4511-92C3-1E9BC9EB728DQ40052007-F9628447-B9FC-47DE-ACDA-CC42DC5DF768Q40053224-60C10748-6922-4A6A-B6FE-1529C858A9D6Q40055103-5DC02328-5D3C-4130-9E5B-A0B4D1D98EB9Q40108631-1F01AE06-F6B6-4C9F-935F-A34ED5BD9D68Q40113278-59DFE1E9-556F-4C22-857B-A53A385AFFBFQ40115327-7682DD94-937C-4D09-B8F7-131A142F34D0Q40125807-1BD8516A-F5E9-4FB4-9493-927227563C0C
P2860
Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.
@en
type
label
Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.
@en
prefLabel
Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.
@en
P2860
P1476
Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.
@en
P2093
Dennis R Burton
Lars Hangartner
P2860
P304
P356
10.1146/ANNUREV-IMMUNOL-041015-055515
P577
2016-05-01T00:00:00Z